The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations

Medicine, Oncology, Pharmacology +15

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Medicine, Hematology, Pharmacology +4

Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

Bhushan Nagar, Oliver Hantschel, Matthew A. Young et al. · Cell · 2003 · 877 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

Evolutionary dynamics of cancer in response to targeted combination therapy

Ivana Božić, Johannes G. Reiter, Benjamin Allen et al. · eLife · 2013 · 647 citations · Full text

Medicine, Cancer Biology, Oncology +14